CGEMCullinan Therapeutics, Inc.

1. Oct 2, 2026On October 1, 2026, the Company announced the initiation of a NDA submission to the FDA for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic NSCLC harboring EGFR ex20ins mutations under the FDA’s RTOR program.Regulation FD disclosure · Form 8-K
2. Sep 24, 2026On September 24, 2026, the Company outlined its plans to share the following immunology and oncology pipeline updates in the fourth quarter of 2026.Regulation FD disclosure · Form 8-K
3. Sep 14, 2026On September 13, 2026, the Company, together with Taiho, announced results from the Phase 3 REZILIENT3 clinical trial evaluating zipalertinib plus chemotherapy versus chemotherapy alone in the first-line treatment of patients with EGFR ex20ins NSCLC. After a safety lead-in (n=6), a total of 279 advanced NSCLC patients …Regulation FD disclosure · Form 8-K
4. Aug 13, 2026On August 12, 2026, the Company and Taiho announced that the REZILIENT3 clinical trial met its primary endpoint of PFS at a planned interim analysis.Regulation FD disclosure · Form 8-K
5. Jun 10, 2026CLN-978 On June 10, 2026, the Company shared updated clinical data from its Phase 1 OUTRACE clinical trials for CLN-978 in patients with treatment-refractory RA (“OUTRACE RA”) and in patients with treatment-refractory moderate to severe SLE (“OUTRACE SLE”)Regulation FD disclosure · Form 8-K
6. Jun 8, 2026On June 6, 2026, the Company shared initial clinical data from its Phase 1 OUTRACE clinical trials for CLN-978 in patients with treatment-refractory RA ("OUTRACE RA") and in patients with treatment-refractory moderate to severe SLE ("OUTRACE SLE")Regulation FD disclosure · Form 8-K
7. May 18, 2026On May 18, 2026, the Company announced initial clinical data from its Phase 1 OUTRACE Program for CLN-978 in patients with treatment-refractory RA and in patients with treatment-refractory moderate to severe SLE. As of a January 14, 2026 cutoff date, 14 patients were dosed across the RA (cohorts 1-3, n=5) and SLE …Regulation FD disclosure · Form 8-K
8. Jan 8, 2026On January 8, 2026, the Company provided an update on the anticipated program milestones for 2026 as set out below.Earnings release · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.